Prostate cancer: Outcomes of active surveillance

**Poster Session 75**

**Monday, 14 March**
**14:00 - 15:30**

**Location:** Room Madrid (Hall B2, level 0)

**Chairs:**
- A.R. Azzouzi, Angers (FR)
- A. Finelli, Toronto (CA)
- T. Pickles, Vancouver (CA)

**Aims and objectives of this presentation**

The session focuses on outcomes of active surveillance

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

**949**

**Long-term quality of life outcomes after active surveillance or curative treatment for prostate cancer**

*By:* Venderbos L.D.F.¹, Aluwini S.A.², Roobol M.J.¹, Bokhorst L.P.¹, Oomens E.H.G.M.³, Bangma C.H.¹, Korfage I.J.⁴

*Institutes:* Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, Erasmus MC, Dept. of Radiology, Rotterdam, The Netherlands, Amphia Hospital, Dept. of Urology, Breda, The Netherlands, Erasmus MC, Dept. of Public Health, Rotterdam, The Netherlands

**950**

**Comparative analysis of immediate vs delayed prostatectomy in prostate cancer patients eligible for active surveillance**

*By:* Mallya A.¹, Karthikeyan V.S.¹, Sivaraman A.², Sanchez-Salas R.², Galiano M.², Rozet F.², Barret E.², Cathelineau X.²

*Institutes:* Institute of Nephrourology, Dept. of Urology, Bangalore, India, Institut Mutualiste Montsouris, Dept. of Urology, Paris, France

**951**

**Use of initial active surveillance among men with low-risk prostate cancer**

*By:* Finelli A.¹, Komisarenko M.², Timilmshina N.², Ahmad A.², Alibhai S.², Zlotta A.⁵, Hamilton R.², Kulkarni G.², Fleshner N.²

*Institutes:* Princess Margaret Hospital, Dept. of Surgical Oncology, Toronto, Canada, Princess Margaret Cancer Centre, Dept. of Surgical Oncology, Toronto, Canada, University of Toronto, Dept. of Health Services, Toronto, Canada, Toronto General Hospital, Dept. of Internal Medicine, Toronto, Canada, Mount Sinai Hospital, Dept. of Surgical Oncology, Toronto, Canada

**952**

**Active surveillance (AS) following transperineal template guided saturation biopsy (TPSB) demonstrates a low rate of progression and conversion to radical treatment, with age and PSA associated with upgrading, upstaging and treatment**

*By:* Sarkar D., Parr N.J.

*Institutes:* Wirral University Teaching Hospital, Dept. of Urology, Wirral, United Kingdom

**953**

**Reclassified in active surveillance for prostate cancer: Was it worthwhile taking the risk?**

*By:* Hefermehl L., Lehmann K.

*Institutes:* Kantonsspital Baden, Dept. of Urology, Baden, Switzerland

**954**

**Longitudinal assessment of general health related QoL in Japanese patients undergoing active surveillance (AS): From an interim analysis of PRIAS-JAPAN**

*By:* Sugimoto M., Hira H., Kakehi Y.

*Institutes:* Kagawa University, Dept. of Urology, Kagawa, Japan
Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared to standard 12-core systematic biopsies for selection of prostate cancer patients for active surveillance
Institutes: 1University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, 2University Hospital Cologne, Dept. of Urology, Cologne, Germany, 3German Cancer Research Center, Dept. of Radiology, Heidelberg, Germany, 4Heinrich-Heine University, Dept. of Radiology, Düsseldorf, Germany, 5University Hospital Berne, Dept. of Urology, Berne, Switzerland, 6Heidelberg University, Dept. of Pathology, Heidelberg, Germany

Stability of health-related quality of life of patients included in an active surveillance program for prostate cancer
By: De La Peña E., Guijarro A., Hernández V., Fernández E., De La Morena J.M., Pozo C., Llorente C.
Institutes: 1Hospital Universitario Fundación Alcorcón, Dept. of Urology, Alcorcon, Spain, 2Hospital Universitario Fundación Alcorcón, Dept. of Research, Alcorcon, Spain

A single center comparison between protocol based (PRIAS) and non-protocol based (ERSPC) prostate cancer active surveillance cohorts
By: Kalalahti I., Vasarainen H., Rannikko A.
Institutes: Helsinki University Central Hospital and University of Helsinki, Dept. of Urology, Helsinki, Finland

Integrating large datasets for the Movember Global Action Plan on active surveillance for low risk prostate cancer
By: Hulsen T., Obbink H., Van Der Linden W., De Jonge C., Nieboer D., Bruinsma S., Roobol M., Bangma C.

HAROW - a prospective non-interventional study comparing treatment options in localized prostate cancer: Observation of “active surveillance” patients with a mean follow up of 47.6 months
By: Herden J., Schnell D., Weissbach L.
Institutes: 1University Hospital Cologne, Dept. of Urology, Cologne, Germany, 2Stiftung Männergesundheit, Fondation of Men’s Health, Berlin, Germany

Summary and context
T. Pickles, Vancouver (CA)